Combination effects of enalapril and losartan on lipid peroxidation in the kidneys of KK-Ay/Ta mice

Nephron - Experimental Nephrology

Volumn 113, Issue 2, 2009, Pages

  Yamazaki, Takahiko ^a   Tanimoto, Mitsuo ^a   Gohda, Tomohito ^a   Ohara, Ikko ^a   Hagiwara, Shinji ^a   Murakoshi, Maki ^a   Matsumoto, Masakazu ^a   Kaneko, Shigeru ^a   Aoki, Tatsuya ^a   Toyoda, Hitoe ^a   Ishikawa, Yuji ^a   Funabiki, Kazuhiko ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Adiponectin; AMPK; Diabetic nephropathy; Lipid peroxidation; RAS inhibitor

Indexed keywords

4 HYDROXYNONENAL; 6 N CARBOXYMETHYLLYSINE; ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ADIPONECTIN; ALBUMIN; CHOLESTEROL; CREATININE; DRINKING WATER; ENALAPRIL; GLUCOSE; HEMOGLOBIN A1C; HYDRALAZINE; INSULIN; LOSARTAN; MALONALDEHYDE; PHOSPHOACETYL COENZYME A CARBOXYLASE BETA; PHOSPO AMP KINASE ALPHA; TAP WATER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVATION; GLOMERULUS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY PARENCHYMA; LIPID PEROXIDATION; MALE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DRUG SYNERGISM; ENALAPRIL; KIDNEY; LIPID PEROXIDATION; LOSARTAN; MALE; MICE;

EID: 67650501025     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228714     Document Type: Article

References (35)

1. Carling D, Zammit VA, Hardie DG: A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 1997; 223: 217-222.
2. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ: AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004; 279: 12005-12008. (Pubitemid 38445761)
3. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, Jennings IG, Iseli T, Michell BJ, Witters LA: AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003; 31: 162-168.
4. Hue L, Beauloye C, Marsin AS, Bertrand L, Horman S, Rider MH: Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J Mol Cell Cardiol 2002; 34: 1091-1097.
5. Tomita K, Tamiya G, Ando S, Kitamura N, Koizumi H, Kato S, Horie Y, Kaneko T, Azuma T, Nagata H, Ishii H, Hibi T: AICAR, an AMPK activator, has protective effects on alcohol- induced fatty liver in rats. Alcohol Clin Exp Res 2005; 29(12 suppl):240S-245S.
6. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295.
7. Cammisotto P, Londono I, Gingras D, Bendayan M: Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats. Am J Physiol Renal Physiol 2008; 294:F881-F889.
8. Sharma K, Remachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ: Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656.
9. Horie K, Miyata T, Maeda K, et al: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100: 2995-3004.
10. Gugliucci A, Bendeyan M: Renal fate of circulating advanced glycated end product (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetlozaia 2006; 39: 149-160.
11. Cohen MP, Ziyadeh FN: Role of Amadorimodified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 183-190.
12. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW: Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34: 10872-10878.
13. Nangaku M, Miyata T, Sada T, et al: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222.
14. Furuhashi M, Ura N, Higashiura K, et al: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
15. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y: Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020.
16. Ito T, Tanimoto M, Watanabe M, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Wakabayashi M, Gohda T, Funabiki K, Horikoshi S, Tomino Y: Glomerular changes in the KK-A y /Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrolog 2006; 11: 29-35.
17. Sasaki M, Uehara S, Ohta H, Taguchi K, Kemi M, Nishikibe M, Matsumoto H: Losartan ameliorates progression of glomerular structural changes in KKAy mice. Life Sci 2004; 75: 869-880.
18. Kumar D, Zimpelmann J, Robertson S, Burns KD: Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. Nephron Exp Nephrol 2004; 96:e77-e88.
19. Okazaki M, Saito Y, Udaka Y, et al: Diabetic nephropathy in KK and KK-A y mice. Exp Anim 2002; 51: 191-196.
20. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ 1998; 38: 703-713.
21. Weinberg MS, Weiberg AJ, Cord R, Zappe DH: The effect of high dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst. 2001; 2(suppl):S196-S198.
22. Abu-Elheiga L, Oh W, Kordari P, Wakil SJ: Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high- carbohydrate diets. Proc Natl Acad Sci USA 2003; 100: 10207-10212.
23. Merrill GF, Kurth EJ, Hardie DG, Winder WW: AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol Endocrinol Metab 1997; 273:E1107-E1112.
24. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kashinath BS: A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 2007; 292: F617-F627.
25. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
26. Rashid G, Benchetrit S, Fishman D, Bernheim J: Effect of advanced glycation endproducts on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004; 66: 1099-1106.
27. Morcos M, Sayed AA, Bierhaus A, et al: Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002; 51: 3532-3544.
28. Nangaku M, Izuhara Y, Usuda N, Inagi R, Shibata T, Sugiyama S, Kurokawa K, van Ypersele de Strihou C, Miyata T: In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant 2005; 20: 2661-2669.
29. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, Strihou CVYD, Kurokawa K: Antihypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222.
30. Miyata T, Kurokawa K: A detective story for biomedical footprints towards new therapeutic interventions in diabetic nephropathy. Intern Med 2003; 42: 1165-1171. Review.
31. Mogensen CE, Neldam S, Tikkanen I, et al: Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminemia, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminemia (CALM) study. BMJ 2000; 321: 1440-1444.
32. Rossing K, Jacobsen P, Pietraszek L, Parking HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 2003; 26: 2268-2274.
33. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 511-512.
34. Kim SM, Huang Y, Qin Y, Mizel D, Schnermann J, Briggs JP: Persistence of circadian variation in arterial blood pressure in beta1/ beta2-adrenergic receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 2008; 294:R1427-R1434.
35. Mathew R, Futterweit S, Valderrama E, Tarectecan AA, Bylander JE, Bond JS, Trachtman H: Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Am J Physiol Renal Physiol 2005; 289:F911-F921.